This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Idexx Laboratories (IDXX) Stock Moves -0.76%: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $487.66 in the latest trading session, marking a -0.76% move from the prior day.
New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD
by Zacks Equity Research
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients
by Zacks Equity Research
PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.
Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19
by Zacks Equity Research
Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.
Cooper Companies' (COO) Unit Assigns Vuzix M400 Smart Glasses
by Zacks Equity Research
Cooper Companies' (COO) unit assigns smart glasses to boost productivity in operations.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes
by Zacks Equity Research
IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.
Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA
by Zacks Equity Research
For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.
Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.
Encompass Health (EHC) Continues to Expand Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) plans to construct a hospital in Texas for offering improved rehabilitative services, which highlights its efforts to bolster presence in the state.
Masimo's (MASI) EMMA Favored by New Study for Children
by Zacks Equity Research
The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.
NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies
by Zacks Equity Research
NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine
by Zacks Equity Research
Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.
Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care
by Zacks Equity Research
Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Cardinal Health (CAH) Inks Deal to Divest Cordis Business
by Zacks Equity Research
Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about robust demand for Hill-Rom's (HRC) product as well as its solid first-quarter fiscal 2021 results.
IDEXX Laboratories (IDXX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
IDEXX Laboratories (IDXX) has been struggling lately, but the selling pressure may be coming to an end soon